14 reports

HALMRE-## - DRUG PROFILE POLLINEX QUATTRO GRASS - DRUG PROFILE Drug Name Company/ Institute Name Licensed From Company Development Partner Product Description Pollinex Quattro Grass Allergy Therapeutics Plc NA GlaxoSmithKline Plc R& D Progress Resea

  • Allergy Drug
  • Ophthalmic Solution
  • Pharmaceutical
  • Respiratory Disease
  • Product Initiative

Oneness Biotech Co Ltd (Oneness Biotech) is a biopharmaceutical company that conducts research and development of drugs.

  • Allergy Drug
  • Allergy Immunotherapy
  • Cardiovascular Disease
  • Respiratory Disease
  • Glenmark Pharmaceuticals Ltd.

THE DRUG CANDIDATE ACTS BY TARGETING DIPEPTIDASE-##.

  • Antifungal
  • Blood Disease
  • Cardiovascular Disease
  • Respiratory Disease
  • Bristol-Myers Squibb Company

The drug candidate is in Phase II stage for peanut allergy in adults and pediatrics, grass pollen allergy and dermatitis globally.

  • Antifungal
  • Cardiovascular Disease
  • Monoclonal Antibody
  • Respiratory Disease
  • United States

Patients were randomized in a ##:## fashion to active drug versus placebo.

  • Cardiovascular Disease
  • Monoclonal Antibody
  • Respiratory Disease
  • United States
  • Product Initiative

THE DRUG CANDIDATE IS A ## MER PEPTIDE ACTS BY TARGETING PROGRAMMED CELL DEATH ## LIGAND ## (PD-L##).

  • Blood Disease
  • Cardiovascular Disease
  • Cell Therapy
  • Respiratory Disease
  • Bristol-Myers Squibb Company

The drug candidate is in Phase II stage for peanut allergy in adults and pediatrics, grass pollen allergy and dermatitis globally.

  • Antifungal
  • Cardiovascular Disease
  • Digestive System Disorder
  • Respiratory Disease
  • United States

About ## percent of people who have food allergies are allergic to more than one food.

  • Cardiovascular Disease
  • Respiratory Disease
  • Therapy
  • United States
  • Product Initiative

ABOUT ## PERCENT OF PEOPLE WHO HAVE FOOD ALLERGIES ARE ALLERGIC TO MORE THAN ONE FOOD.

  • Cardiovascular Disease
  • Respiratory Disease
  • Targeted Therapy
  • United States
  • Product Initiative

In July 2011, Oxagen Limited announced publication of data from a Phase IIa clinical trial of its development drug OC## in the journal Clinical & Experimental Allergy.

  • Cardiovascular Disease
  • Pharmaceutical
  • Respiratory Disease
  • United States
  • Product Initiative

One group was given ##mg of the drug twice a day for ## weeks and the other participants were assigned to a placebo group.

  • Cardiovascular Disease
  • Pharmaceutical
  • Respiratory Disease
  • United States
  • Product Initiative

THE DRUG CANDIDATE IS IN PHASE II STAGE FOR PEANUT ALLERGY IN ADULTS AND PEDIATRICS, GRASS POLLEN ALLERGY AND DERMATITIS GLOBALLY.

  • Cardiovascular Disease
  • Respiratory Disease
  • Therapy
  • United States
  • Product Initiative

Two out of the six were considered possibly related to study drug: one in Group ## and one in Group ##.

  • Antifungal
  • Cardiovascular Disease
  • Respiratory Disease
  • United States
  • SCYNEXIS, Inc.

THE DRUG CANDIDATE IS IN PHASE II STAGE FOR PEANUT ALLERGY IN ADULTS AND PEDIATRICS, GRASS POLLEN ALLERGY AND DERMATITIS GLOBALLY.

  • Antifungal
  • Cardiovascular Disease
  • Clinical Trial
  • Respiratory Disease
  • AstraZeneca PLC